EMB-09 is under clinical development by EpimAb Biotherapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase ...

By decoding how focal adhesions regulate lysosomal exocytosis, researchers are opening new doors to understanding cancer cell adhesion and migration and exploring innovative therapies targeting ...

The 5-year relative survival rate for most cancers have improved in the last 40 years. The only exceptions are uterine (endometrial) cancer and cervical cancer—whose survival rates have declined.

Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...

—A new study from California-based researchers reports that things may be getting worse for certain women at risk for endometrial cancer. Here’s what the research team adds to what’s known ...

The use of peritoneal washing for determining the prognosis and treatment for endometrial cancer, especially in its early stages, is debated in the medical community. Peritoneal washing is performed ...

Objective: The 2013 TCGA identified four molecular subgroups of endometrial cancer; however, the data results for most of the pathological features were varied and of low value for clinical ...

Focal therapy aims to find a middle ground between surveillance and radical therapies by treating the cancer alone, with a margin, and preserving as much tissue as is practical. Early feasibility ...

This systematic review reports on the efficacy and safety of focal brachytherapy for treatment of patients with localized prostate cancer. Medline, Embase, Web of Science and Cochrane were searched ...